Scaleup

Jul
31

Main Sequence & top US sustainability VCs lead $US28m Series B for Australian breakthrough mining tech Plotlogic

US and Australian venture capital climate and sustainability heavyweights have led a $US28 million Series B funding round for deep-tech mining company Plotlogic.

DETAIL
Jul
19

NSW & QLD’s best entrepreneurs to clash at Battle of the Founders thanks to Gold Coast Innovation Hub, Fishburners, OnMarket and Advance Queensland

The Battle of the Founders is the ultimate showdown of innovation, bringing together some of the most promising entrepreneurs across Australia.

DETAIL
Jul
19

MongoDB partners with Microsoft StartUps – gives free access to data platform Atlas to support data-driven innovation

MongoDB and Microsoft are committing to a broad range of initiatives to make it easier for customers to advance their cloud adoption journeys.

DETAIL
Jul
18

3 important AI lessons for start-ups and scale-ups from entrepreneur Nick Bell

If you’ve been hiding under your desk from AI, you’re not alone, says Nick Bell, young rich-lister and owner of the Superist Group.

DETAIL
Jul
18

Glow Capital Partners acquires 51% of modern uniform brand Cargo Crew

Cargo Crew announce Glow Capital Partners will acquire 51% of the business to help take the company from a cult Australian hospitality brand to a leading global brand.

DETAIL
Jul
15

Australian cosmetic chain Cosmetique continues national expansion as ‘lipstick effect’ takes hold

Cosmetique has accelerated its national expansion plans as consumer spending on feel good treatments and beauty products and services rises.

DETAIL
Jun
30

Melbourne’s best bars have joined EatClub to reach more diners as inflation bites

EatClub, the world’s first dynamic pricing platform for restaurants has recently expanded its highly popular app to include bars and clubs, and the move is proving highly successful with diners.

DETAIL
Jun
05

ImmVirX raising $25m led by renowned healthcare VC OneVentures

ImmVirX Pty Limited has announced that it is raising up to A$25 million via Series B preference shares (“Offer”), funding the Company’s clinical development through to 2026.

DETAIL